Head to Head Contrast: Organon & Co. (NYSE:OGN) vs. Revvity (NYSE:RVTY)

Revvity (NYSE:RVTY) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Profitability

This table compares Revvity and Organon & Co.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revvity	10.19%	7.66%	4.73%
Organon & Co.	11.15%	163.88%	6.99%

Analyst Ratings

This is a summary of current ratings and recommmendations for Revvity and Organon & Co., as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	1	5	9	0	2.53
Organon & Co.	1	2	2	1	2.50

Revvity currently has a consensus price target of $116.62, indicating a potential upside of 24.59%. Organon & Co. has a consensus price target of $17.33, indicating a potential upside of 86.78%. Given Organon & Co.’s higher possible upside, analysts plainly believe Organon & Co. is more favorable than Revvity.

Dividends

Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.3%. Organon & Co. pays an annual dividend of $0.08 per share and has a dividend yield of 0.9%. Revvity pays out 11.9% of its earnings in the form of a dividend. Organon & Co. pays out 3.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Organon & Co. is clearly the better dividend stock, given its higher yield and lower payout ratio.

Risk and Volatility

Revvity has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.

Earnings & Valuation

This table compares Revvity and Organon & Co.”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revvity	$2.76 billion	3.94	$270.39 million	$2.36	39.66
Organon & Co.	$6.40 billion	0.38	$864.00 million	$2.69	3.45

Organon & Co. has higher revenue and earnings than Revvity. Organon & Co. is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

86.7% of Revvity shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 0.7% of Revvity shares are owned by insiders. Comparatively, 2.0% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Organon & Co. beats Revvity on 11 of the 17 factors compared between the two stocks.

About Revvity

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

About Organon & Co.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.